Payment overview · 2025
General Payments
$440.75
27 reported records · 13 companies
Healthcare provider profile · identity verified
John C. Shehan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · OMAHA, NE · NPI 1902800287
Verified facts
What the public records show
CMS Open Payments records show John C. Shehan, M.D. received $440.75 in general payments during 2025 across 27 reported records.
JAZZ PHARMACEUTICALS INC. accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $86.57 | 19.6% | 4 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $77.55 | 17.6% | 5 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $71.79 | 16.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.49 | 9.6% | 3 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $37.71 | 8.6% | 4 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $17.42 | 4.0% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $16.61 | 3.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.13 | 3.7% | 1 | 2025 |
| La Jolla Pharmaceutical Company | Unresolved — no canonical attribution shown | $15.53 | 3.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.41 | 3.5% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $14.65 | 3.3% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $14.63 | 3.3% | 1 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $14.26 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $440.75 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $86.57 | 4 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $77.55 | 5 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $71.79 | 3 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $37.71 | 4 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc. | $28.78 | 2 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| GIAPREZA Normalized: giapreza |
Drug | La Jolla Pharmaceutical Company | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
133 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 418 | 143 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 354 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 209 | 67 |
| Montelukast Sodium | Montelukast Sodium | 204 | 41 |
| Doxycycline Hyclate | Doxycycline Hyclate | 153 | 98 |
| Breo Ellipta | Fluticasone/Vilanterol | 138 | 34 |
| Eliquis | Apixaban | 133 | 12 |
| Gabapentin | Gabapentin | 89 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 79 | 17 |
| Furosemide | Furosemide | 66 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 58 | suppressed |
| Omeprazole | Omeprazole | 55 | 13 |
| Azithromycin | Azithromycin | 50 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 22 |
| Ventolin Hfa | Albuterol Sulfate | 50 | 16 |
| Enoxaparin Sodium | Enoxaparin Sodium | 48 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 48 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | 16 |
| Incruse Ellipta | Umeclidinium Bromide | 47 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 43 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 42 | suppressed |
| Methylprednisolone | Methylprednisolone | 40 | 28 |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Modafinil | Modafinil | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Torsemide | Torsemide | 37 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 36 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 35 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Famotidine | Famotidine | 32 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 32 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 14 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Novolin R | Insulin Regular, Human | 24 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Armodafinil | Armodafinil | 22 | suppressed |
| Cefdinir | Cefdinir | 22 | 18 |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 21 | suppressed |
| Budesonide | Budesonide | 21 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Acetylcysteine | Acetylcysteine | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Metformin Hcl | Metformin Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $440.75 · 27 records | JAZZ PHARMACEUTICALS INC. | Arikayce, Da Vinci Surgical System, GIAPREZA, INSPIRE, JASCAYD, LUMRYZ, OCTAGAM IMMUNE GLOBULIN (HUMAN), PANZYGA, SMARTVEST, TAVNEOS, TEZSPIRE, Vest Therapy Und, WAKIX, XYWAV | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error